Cargando…

Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review

HYPOTHESIS/OBJECTIVES: Early prevention of diabetic nephropathy by way of blocking the renin-angiotensin system (RAS) in patients with normoalbuminuria seems rational, but trials have so far shown conflicting results. The present meta-analysis was undertaken to investigate if such treatment can prev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Persson, Frederik, Lindhardt, Morten, Rossing, Peter, Parving, Hans-Henrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843870/ https://www.ncbi.nlm.nih.gov/pubmed/27488274 http://dx.doi.org/10.1177/1470320316652047

Ejemplares similares

Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria: An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy
por: Broedbaek, Kasper, et al.
Publicado: (2011)

Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria
por: Currie, Gemma E., et al.
Publicado: (2018)

Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: A post hoc analysis of the IRMA-2 trial
por: Hellemons, Merel E., et al.
Publicado: (2011)

Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria
por: Andersen, Sten, et al.
Publicado: (2010)

Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria
por: Zobel, Emilie H., et al.
Publicado: (2017)

Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial
por: Gæde, Peter, et al.
Publicado: (2016)

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial
por: Lindhardt, Morten, et al.
Publicado: (2016)

Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study
por: Oellgaard, Jens, et al.
Publicado: (2018)

Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria
por: Reinhard, Henrik, et al.
Publicado: (2011)

Marker for kidney fibrosis is associated with inflammation and deterioration of kidney function in people with type 2 diabetes and microalbuminuria
por: Poulsen, Christina Gjerlev, et al.
Publicado: (2023)

Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors
por: Eickhoff, Mie K., et al.
Publicado: (2019)

Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes
por: Gnudi, Luigi, et al.
Publicado: (2010)

Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy
por: Persson, Frederik, et al.
Publicado: (2010)

NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis
por: Reinhard, Henrik, et al.
Publicado: (2011)

Aggressive versus Low Dose Inhibition of the Renin-Angiotensin System for the Treatment of Microalbuminuria in Type 2 Diabetic Patients: A Pilot Study
por: Davidson, M. B., et al.
Publicado: (2011)

Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus
por: Pena, Michelle J., et al.
Publicado: (2016)

Reduction of microalbuminuria in type-2 diabetes mellitus with angiotensin-converting enzyme inhibitor alone and with cilnidipine
por: Singh, V. K., et al.
Publicado: (2015)

Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes
por: von Scholten, Bernt Johan, et al.
Publicado: (2015)

Tissue Renin–Angiotensin Systems: A Unifying Hypothesis of Metabolic Disease
por: Skov, Jeppe, et al.
Publicado: (2014)

Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes – An observational follow-up study
por: Frimodt-Møller, Marie, et al.
Publicado: (2018)

Do inhibitors of the renin–angiotensin system prevent chronic kidney disease?
por: Rayner, Brian
Publicado: (2010)

Renin‐Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID‐19
por: Loader, Jordan, et al.
Publicado: (2021)

Does antihypertensive treatment with renin-angiotensin system inhibitors prevent the development of diabetic kidney disease?
por: Miyazaki, Hiroki, et al.
Publicado: (2015)

Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria
por: Persson, Frederik, et al.
Publicado: (2009)

Vitamin D Levels, Microvascular Complications, and Mortality in Type 1 Diabetes
por: Joergensen, Christel, et al.
Publicado: (2011)

Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3‐deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub‐study
por: Piazza, M., et al.
Publicado: (2020)

Angiotensin type 1a receptor-deficient mice develop diabetes-induced cardiac dysfunction, which is prevented by renin-angiotensin system inhibitors
por: Yong, Qian Chen, et al.
Publicado: (2013)

The renin–angiotensin system and diabetes: An update
por: Ribeiro-Oliveira, Antônio, et al.
Publicado: (2008)

Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
por: Benenson, Irina, et al.
Publicado: (2020)

Serum Uric Acid as a Predictor for Development of Diabetic Nephropathy in Type 1 Diabetes: An Inception Cohort Study
por: Hovind, Peter, et al.
Publicado: (2009)

Prevention and management of hyperkalemia in patients treated with renin–angiotensin–aldosterone system inhibitors
por: Weinstein, Jordan, et al.
Publicado: (2021)

Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin–angiotensin system inhibitors in type 2 diabetic patients with albuminuria
por: Cooper, Mark E., et al.
Publicado: (2019)

Vitamin D Levels and Mortality in Type 2 Diabetes
por: Joergensen, Christel, et al.
Publicado: (2010)

Chronotherapy with a Renin-angiotensin System Inhibitor Ameliorates Renal Damage by Suppressing Intrarenal Renin-angiotensin System Activation
por: Aoki, Taro, et al.
Publicado: (2020)

Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19
por: Jarcho, John A., et al.
Publicado: (2020)

Hypothesis for renin-angiotensin inhibitor mitigation of COVID-19
por: Sackin, Henry
Publicado: (2021)

Renin–Angiotensin–Aldosterone Inhibitors and COVID-19 Infection
por: Tsampasian, Vasiliki, et al.
Publicado: (2022)

Osteoprotegerin and Mortality in Type 2 Diabetic Patients
por: Reinhard, Henrik, et al.
Publicado: (2010)

Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy
por: Lajer, Maria, et al.
Publicado: (2010)

What’s new in the renin-angiotensin system?: What’s new in the renin-angiotensin system?
por: Smith, A. I., et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_gbcmg3tcaegbp089j3t1fm3bbe